Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives:

* To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
* To determine the response rate of the recommended dose
* To determine the safety and tolerability of the recommended dose
Head and Neck Neoplasms
DRUG: Docetaxel
AE SAE collection, from the inform consent signed up to the end of the study
Study Objectives:

* To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
* To determine the response rate of the recommended dose
* To determine the safety and tolerability of the recommended dose